ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022: Phase II Study of Inotuzumab Ozogamicin for the Treatment of MRD+ B-Cell ALL
By
ASH 2022 Conference Coverage
FEATURING
Jajastu Senapati
By
ASH 2022 Conference Coverage
FEATURING
Jajastu Senapati
52 views
December 16, 2022
Login to view comments.
Click here to Login
Leukemia